Skip to main content
Top
Published in: Diagnostic Pathology 1/2021

Open Access 01-12-2021 | Foreign Body Aspiration | Research

Diagnostic performance of Midkine ratios in fine-needle aspirates for evaluation of Cytologically indeterminate thyroid nodules

Authors: Le Zhou, Jinxi Jiang, Yantao Fu, Daqi Zhang, Tong Li, Qingfeng Fu, Chao Yan, Yifan Zhong, Gianlorenzo Dionigi, Nan Liang, Hui Sun

Published in: Diagnostic Pathology | Issue 1/2021

Login to get access

Abstract

Background

Fine-needle aspiration cytology (FNAC) is a basic diagnostic tool for thyroid nodules. However, 15–30% of nodules are cytologically indeterminate. Midkine (MK), a pleiotropic growth factor, is often upregulated in patients with cancers. This study aimed to evaluate the role of MK and its ratios in fine-needle aspirates (FNA) for predicting thyroid malignancy.

Methods

This retrospective study included patients with thyroid nodules who underwent preoperative FNA and/or thyroidectomy between April 2017 and September 2017. MK levels in FNA washout were measured by enzyme-linked immunosorbent assay, and thyroglobulin (TG) and free thyroxine (FT4) levels in FNA washout were measured by chemiluminescent immunometric assays.

Results

A total of 217 patients with 242 nodules were included in this study. The concentrations of TG, FT4, MK/TG, MK/FT4, and FT4/MK were significantly different between papillary thyroid carcinomas and benign thyroid nodules. Both MK/TG and MK/FT4 ratios were positively correlated with maximum tumor diameter, extrathyroidal extension, and T and N stages. The area under the curve for MK/TG was 0.719 with a cutoff value of 55.57 ng/mg, while the area under the curve for MK/FT4 was 0.677 with a cutoff value of 0.11 μg/pmol. FNAC in combination with MK/FT4 had a higher sensitivity (95% vs. 91%) and accuracy (96% vs. 92%) than FNAC alone for cytologically indeterminate specimens, those of unknown significance, or those suspected of malignancy.

Conclusions

MK/FT4 and MK/TG may have diagnostic utility for evaluation of papillary thyroid carcinomas, particularly for cytologically indeterminate thyroid nodules.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kadomatsu K, Kishida S, Tsubota S. The heparin-binding growth factor midkine: the biological activities and candidate receptors. J Biochem. 2013;153(6):511–21.CrossRef Kadomatsu K, Kishida S, Tsubota S. The heparin-binding growth factor midkine: the biological activities and candidate receptors. J Biochem. 2013;153(6):511–21.CrossRef
2.
go back to reference Shao H, Yu X, Wang C, Wang Q, Guan H. Midkine expression is associated with clinicopathological features and BRAF mutation in papillary thyroid cancer. Endocrine. 2014;46(2):285–91.CrossRef Shao H, Yu X, Wang C, Wang Q, Guan H. Midkine expression is associated with clinicopathological features and BRAF mutation in papillary thyroid cancer. Endocrine. 2014;46(2):285–91.CrossRef
3.
go back to reference Ikematsu S, Okamoto K, Yoshida Y, Oda M, Sugano-Nagano H, Ashida K, et al. High levels of urinary midkine in various cancer patients. Biochem Biophys Res Commun. 2003;306(2):329–32.CrossRef Ikematsu S, Okamoto K, Yoshida Y, Oda M, Sugano-Nagano H, Ashida K, et al. High levels of urinary midkine in various cancer patients. Biochem Biophys Res Commun. 2003;306(2):329–32.CrossRef
4.
go back to reference Jee YH, Celi FS, Sampson M, Sacks DB, Remaley AT, Kebebew E, et al. Midkine concentrations in fine-needle aspiration of benign and malignant thyroid nodules. Clin Endocrinol. 2015;83(6):977–84.CrossRef Jee YH, Celi FS, Sampson M, Sacks DB, Remaley AT, Kebebew E, et al. Midkine concentrations in fine-needle aspiration of benign and malignant thyroid nodules. Clin Endocrinol. 2015;83(6):977–84.CrossRef
5.
go back to reference American Thyroid Association Guidelines Taskforce on Thyroid N, Differentiated Thyroid C, Cooper DS, Doherty GM, Haugen BR, Kloos RT, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–214.CrossRef American Thyroid Association Guidelines Taskforce on Thyroid N, Differentiated Thyroid C, Cooper DS, Doherty GM, Haugen BR, Kloos RT, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–214.CrossRef
6.
go back to reference Patel HH, Goyal N, Goldenberg D. Imaging, genetic testing, and biomarker assessment of follicular cell-derived thyroid cancer. Ann Med. 2014;46(6):409–16.CrossRef Patel HH, Goyal N, Goldenberg D. Imaging, genetic testing, and biomarker assessment of follicular cell-derived thyroid cancer. Ann Med. 2014;46(6):409–16.CrossRef
7.
go back to reference Garino F, Deandrea M, Motta M, Mormile A, Ragazzoni F, Palestini N, et al. Diagnostic performance of elastography in cytologically indeterminate thyroid nodules. Endocrine. 2015;49(1):175–83.CrossRef Garino F, Deandrea M, Motta M, Mormile A, Ragazzoni F, Palestini N, et al. Diagnostic performance of elastography in cytologically indeterminate thyroid nodules. Endocrine. 2015;49(1):175–83.CrossRef
8.
go back to reference Pacini F, Fugazzola L, Lippi F, Ceccarelli C, Centoni R, Miccoli P, et al. Detection of thyroglobulin in fine needle aspirates of nonthyroidal neck masses: a clue to the diagnosis of metastatic differentiated thyroid cancer. J Clin Endocrinol Metab. 1992;74(6):1401–4.PubMed Pacini F, Fugazzola L, Lippi F, Ceccarelli C, Centoni R, Miccoli P, et al. Detection of thyroglobulin in fine needle aspirates of nonthyroidal neck masses: a clue to the diagnosis of metastatic differentiated thyroid cancer. J Clin Endocrinol Metab. 1992;74(6):1401–4.PubMed
9.
go back to reference Giovanella L, Ceriani L, Suriano S, Crippa S. Thyroglobulin measurement on fine-needle washout fluids: influence of sample collection methods. Diagn Cytopathol. 2009;37(1):42–4.CrossRef Giovanella L, Ceriani L, Suriano S, Crippa S. Thyroglobulin measurement on fine-needle washout fluids: influence of sample collection methods. Diagn Cytopathol. 2009;37(1):42–4.CrossRef
10.
go back to reference Martins-Costa MC, Maciel RMB, Kasamatsu TS, Nakabashi CCD, Camacho CP, Crispim F, et al. Clinical impact of thyroglobulin (Tg) and Tg autoantibody (TgAb) measurements in needle washouts of neck lymph node biopsies in the management of patients with papillary thyroid carcinoma. Arch Endocrinol Metab. 2017;61(2):108–14.CrossRef Martins-Costa MC, Maciel RMB, Kasamatsu TS, Nakabashi CCD, Camacho CP, Crispim F, et al. Clinical impact of thyroglobulin (Tg) and Tg autoantibody (TgAb) measurements in needle washouts of neck lymph node biopsies in the management of patients with papillary thyroid carcinoma. Arch Endocrinol Metab. 2017;61(2):108–14.CrossRef
11.
go back to reference Sohn YM, Kim MJ, Kim EK, Kwak JY. Diagnostic performance of thyroglobulin value in indeterminate range in fine needle aspiration washout fluid from lymph nodes of thyroid cancer. Yonsei Med J. 2012;53(1):126–31.CrossRef Sohn YM, Kim MJ, Kim EK, Kwak JY. Diagnostic performance of thyroglobulin value in indeterminate range in fine needle aspiration washout fluid from lymph nodes of thyroid cancer. Yonsei Med J. 2012;53(1):126–31.CrossRef
12.
go back to reference Kato M, Maeta H, Kato S, Shinozawa T, Terada T. Immunohistochemical and in situ hybridization analyses of midkine expression in thyroid papillary carcinoma. Modern Pathol. 2000;13(10):1060–5.CrossRef Kato M, Maeta H, Kato S, Shinozawa T, Terada T. Immunohistochemical and in situ hybridization analyses of midkine expression in thyroid papillary carcinoma. Modern Pathol. 2000;13(10):1060–5.CrossRef
13.
go back to reference Bao R, Wang X, Wang Q, et al. Expression of Midkine and its relationship with Clinicopathological characteristics and BRAF mutation in papillary thyroid Cancer. J Chin Med Univ. 2010;39:518–20. Bao R, Wang X, Wang Q, et al. Expression of Midkine and its relationship with Clinicopathological characteristics and BRAF mutation in papillary thyroid Cancer. J Chin Med Univ. 2010;39:518–20.
14.
go back to reference Omran MM, Farid K, Omar MA, Emran TM, El-Taweel FM, Tabll AA. A combination of alpha-fetoprotein, midkine, thioredoxin and a metabolite for predicting hepatocellular carcinoma. Ann Hepatol. 2020;19(2):179–85.CrossRef Omran MM, Farid K, Omar MA, Emran TM, El-Taweel FM, Tabll AA. A combination of alpha-fetoprotein, midkine, thioredoxin and a metabolite for predicting hepatocellular carcinoma. Ann Hepatol. 2020;19(2):179–85.CrossRef
15.
go back to reference Zhang BH, Li B, Kong LX, Yan LN, Yang JY. Diagnostic accuracy of midkine on hepatocellular carcinoma: a meta-analysis. PLoS One. 2019;14(10):e0223514.CrossRef Zhang BH, Li B, Kong LX, Yan LN, Yang JY. Diagnostic accuracy of midkine on hepatocellular carcinoma: a meta-analysis. PLoS One. 2019;14(10):e0223514.CrossRef
16.
go back to reference Kuzu F, Arpaci D, Unal M, Altas A, Haytaoglu G, Can M, et al. Midkine: a novel biomarker to predict malignancy in patients with nodular thyroid disease. Int J Endocrinol. 2016;2016:6035024.CrossRef Kuzu F, Arpaci D, Unal M, Altas A, Haytaoglu G, Can M, et al. Midkine: a novel biomarker to predict malignancy in patients with nodular thyroid disease. Int J Endocrinol. 2016;2016:6035024.CrossRef
17.
go back to reference Thomas BS, Bulbrook RD, Goodman MJ, Russell MJ, Quinlan M, Hayward JL, et al. Thyroid function and the incidence of breast cancer in Hawaiian, British and Japanese women. Int J Cancer. 1986;38(3):325–9.CrossRef Thomas BS, Bulbrook RD, Goodman MJ, Russell MJ, Quinlan M, Hayward JL, et al. Thyroid function and the incidence of breast cancer in Hawaiian, British and Japanese women. Int J Cancer. 1986;38(3):325–9.CrossRef
18.
go back to reference Cibas ES, Ali SZ. The 2017 Bethesda system for reporting thyroid cytopathology. Thyroid. 2017;27(11):1341–6.CrossRef Cibas ES, Ali SZ. The 2017 Bethesda system for reporting thyroid cytopathology. Thyroid. 2017;27(11):1341–6.CrossRef
19.
go back to reference Ikematsu S, Yano A, Aridome K, Kikuchi M, Kumai H, Nagano H, et al. Serum midkine levels are increased in patients with various types of carcinomas. Br J Cancer. 2000;83(6):701–6.CrossRef Ikematsu S, Yano A, Aridome K, Kikuchi M, Kumai H, Nagano H, et al. Serum midkine levels are increased in patients with various types of carcinomas. Br J Cancer. 2000;83(6):701–6.CrossRef
20.
go back to reference Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.CrossRef Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.CrossRef
21.
go back to reference Ianni F, Campanella P, Rota CA, Prete A, Castellino L, Pontecorvi A, et al. A meta-analysis-derived proposal for a clinical, ultrasonographic, and cytological scoring system to evaluate thyroid nodules: the “CUT” score. Endocrine. 2016;52(2):313–21.CrossRef Ianni F, Campanella P, Rota CA, Prete A, Castellino L, Pontecorvi A, et al. A meta-analysis-derived proposal for a clinical, ultrasonographic, and cytological scoring system to evaluate thyroid nodules: the “CUT” score. Endocrine. 2016;52(2):313–21.CrossRef
22.
go back to reference Jones DR. Measuring midkine: the utility of midkine as a biomarker in cancer and other diseases. Brit J Pharmacol. 2014;171(12):2925–39.CrossRef Jones DR. Measuring midkine: the utility of midkine as a biomarker in cancer and other diseases. Brit J Pharmacol. 2014;171(12):2925–39.CrossRef
23.
go back to reference AR NZ, El Kassas M, Salam ESE, Hassan RM, Mohanad M, Gabr RM, et al. The possible role of Dickkopf-1, Golgi protein- 73 and Midkine as predictors of hepatocarcinogenesis: a review and an Egyptian study. Sci Rep. 2020;10(1):5156.CrossRef AR NZ, El Kassas M, Salam ESE, Hassan RM, Mohanad M, Gabr RM, et al. The possible role of Dickkopf-1, Golgi protein- 73 and Midkine as predictors of hepatocarcinogenesis: a review and an Egyptian study. Sci Rep. 2020;10(1):5156.CrossRef
24.
go back to reference Kemper M, Hentschel W, Grass JK, Stuben BO, Konczalla L, Rawnaq T, et al. Serum Midkine is a clinical significant biomarker for colorectal cancer and associated with poor survival. Cancer Med. 2020;9(6):2010–8.CrossRef Kemper M, Hentschel W, Grass JK, Stuben BO, Konczalla L, Rawnaq T, et al. Serum Midkine is a clinical significant biomarker for colorectal cancer and associated with poor survival. Cancer Med. 2020;9(6):2010–8.CrossRef
25.
go back to reference Shiratori F, Ito M, Yajima S, Suzuki T, Oshima Y, Nanami T, et al. The effectiveness of serum midkine in detecting esophageal squamous cell carcinoma. Esophagus. 2019;16(3):246–51.CrossRef Shiratori F, Ito M, Yajima S, Suzuki T, Oshima Y, Nanami T, et al. The effectiveness of serum midkine in detecting esophageal squamous cell carcinoma. Esophagus. 2019;16(3):246–51.CrossRef
26.
go back to reference Lin H, Zhou Q, Wu W, Ma Y. Midkine is a potential urinary biomarker for non-invasive detection of bladder Cancer with microscopic hematuria. Onco Targets Ther. 2019;12:11765–75.CrossRef Lin H, Zhou Q, Wu W, Ma Y. Midkine is a potential urinary biomarker for non-invasive detection of bladder Cancer with microscopic hematuria. Onco Targets Ther. 2019;12:11765–75.CrossRef
27.
go back to reference Zhang YJ, Meng ZW, Zhang MF, Tan J, Tian WJ, He XH, et al. Immunohistochemical evaluation of midkine and nuclear factor-kappa B as diagnostic biomarkers for papillary thyroid cancer and synchronous metastasis. Life Sci. 2014;118(1):39–45.CrossRef Zhang YJ, Meng ZW, Zhang MF, Tan J, Tian WJ, He XH, et al. Immunohistochemical evaluation of midkine and nuclear factor-kappa B as diagnostic biomarkers for papillary thyroid cancer and synchronous metastasis. Life Sci. 2014;118(1):39–45.CrossRef
28.
go back to reference Choi YW, Kim YH, Lee J, Soh EY, Park TJ, Kim JH. Strong immunoexpression of midkine is associated with multiple lymph node metastases in BRAFV600E papillary thyroid carcinoma. Hum Pathol. 2015;46(10):1557–65.CrossRef Choi YW, Kim YH, Lee J, Soh EY, Park TJ, Kim JH. Strong immunoexpression of midkine is associated with multiple lymph node metastases in BRAFV600E papillary thyroid carcinoma. Hum Pathol. 2015;46(10):1557–65.CrossRef
29.
go back to reference Muramatsu T. Structure and function of midkine as the basis of its pharmacological effects. Brit J Pharmacol. 2014;171(4):814–26.CrossRef Muramatsu T. Structure and function of midkine as the basis of its pharmacological effects. Brit J Pharmacol. 2014;171(4):814–26.CrossRef
30.
go back to reference Muramatsu T, Kadomatsu K. Midkine: an emerging target of drug development for treatment of multiple diseases. Brit J Pharmacol. 2014;171(4):811–3.CrossRef Muramatsu T, Kadomatsu K. Midkine: an emerging target of drug development for treatment of multiple diseases. Brit J Pharmacol. 2014;171(4):811–3.CrossRef
31.
go back to reference Filippou PS, Karagiannis GS, Constantinidou A. Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target. Oncogene. 2020;39(10):2040–54.CrossRef Filippou PS, Karagiannis GS, Constantinidou A. Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target. Oncogene. 2020;39(10):2040–54.CrossRef
32.
go back to reference Li N, Zhang C, Meng Z, Xu K, He X, Yu Y, et al. Changes of serum midkine as a dynamic prognostic factor to monitor disease status in papillary thyroid cancer. Medicine (Baltimore). 2018;97(36):e12242.CrossRef Li N, Zhang C, Meng Z, Xu K, He X, Yu Y, et al. Changes of serum midkine as a dynamic prognostic factor to monitor disease status in papillary thyroid cancer. Medicine (Baltimore). 2018;97(36):e12242.CrossRef
33.
go back to reference Yang PF, Li J, Zhang JZ, et al. The measurement and clinical significance of Midkine in serum of patients with nodules. J Hubei Univ Sci Technol. 2016;30(1):7–10. Yang PF, Li J, Zhang JZ, et al. The measurement and clinical significance of Midkine in serum of patients with nodules. J Hubei Univ Sci Technol. 2016;30(1):7–10.
34.
go back to reference Jia Q, Meng Z, Xu K, He X, Tan J, Zhang G, et al. Serum midkine as a surrogate biomarker for metastatic prediction in differentiated thyroid cancer patients with positive thyroglobulin antibody. Sci Rep. 2017;7:43516.CrossRef Jia Q, Meng Z, Xu K, He X, Tan J, Zhang G, et al. Serum midkine as a surrogate biomarker for metastatic prediction in differentiated thyroid cancer patients with positive thyroglobulin antibody. Sci Rep. 2017;7:43516.CrossRef
Metadata
Title
Diagnostic performance of Midkine ratios in fine-needle aspirates for evaluation of Cytologically indeterminate thyroid nodules
Authors
Le Zhou
Jinxi Jiang
Yantao Fu
Daqi Zhang
Tong Li
Qingfeng Fu
Chao Yan
Yifan Zhong
Gianlorenzo Dionigi
Nan Liang
Hui Sun
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2021
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/s13000-021-01150-y

Other articles of this Issue 1/2021

Diagnostic Pathology 1/2021 Go to the issue